NCT00626860View on ClinicalTrials.gov

The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2000

Primary Completion Date

January 31, 2002

Study Completion Date

September 10, 2008

Conditions
Metastatic Melanoma
Interventions
BIOLOGICAL

DC/tumor fusion vaccine

SC vaccinations administered to each patient at 3-week intervals for 2-3 doses

Trial Locations (1)

02215

BIDMC, Boston

All Listed Sponsors
collaborator

Genzyme, a Sanofi Company

INDUSTRY

lead

Beth Israel Deaconess Medical Center

OTHER

NCT00626860 - The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma | Biotech Hunter | Biotech Hunter